Compare AstraZeneca plc (AZN) vs iShares MSCI Japan ETF (EWJ) Price & Performance

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

EWJ (iShares MSCI Japan ETF) trades at $98.12, up 2.16% with strong bullish technical signals from moving averages. The ETF benefits from recent U.S.-Japan currency intervention supporting the yen, while facing headwinds from Japan's inflation dynamics and export pressures. Technical indicators show overbought conditions with RSI at 84.79, suggesting potential near-term consolidation.

Outlook remains cautiously optimistic as Japanese equities respond to policy support, though currency volatility and economic uncertainty present risks. The fund's exposure to Japan's export sector faces challenges from yen strength, while domestic stimulus measures could provide upside potential for consumer-focused holdings.